inflammation/albumin

Lyen an sove nan clipboard la

Chwazi kalite sòt

12 rezilta yo

Method for producing albumin conjugates containing gyrase inhibitors

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION The present invention concerns gyrase inhibitor-protein conjugates and in particular gyrase inhibitor-albumin conjugates, pharmaceutical preparations comprising gyrase inhibitor-protein conjugates in particular for the treatment and/or prophylaxis of inflammatory processes

Biomarkers for inflammation of the liver

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

RELATED APPLICATIONS This application is a national stage application (under 35 U.S.C. .sctn.371) of PCT/DE2007/001427, filed Aug. 10, 2007, which claims benefit of German application 102006037613.7, filed Aug. 10, 2006 and German application 102006048249.2, filed Oct. 12, 2006. DESCRIPTION The

Nanoparticle carrier systems based on human serum albumin for photodynamic therapy

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to drug formulation of hydrophobic photosensitizer. In particular, the invention relates to nanoparticle formulations containing hydrophobic photosensitizers, to their method of preparation and to their use in

Compositions and methods for diagnosing or treating neutrophil-mediated inflammatory disease

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION The present invention relates generally to compositions and methods for diagnosing or treating neutrophil-mediated inflammatory disease. BACKGROUND OF THE INVENTION Neutrophil adhesion to activated endothelial cells and trans-endothelial migration of these cells are essential

Method for measuring activity of a specific fraction of albumin

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND OF THE INVENTION The inflammatory response governs a wide range of illness from injury to infections and allergies. Initiating inflammation involves activating immune cells that trigger the phospholipase A.sub.2 (PLA.sub.2)-involved inflammatory processes. PLA.sub.2 enzymes are a diverse

Natural pharmaceutical preparations for increasing albumin

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND OF THE PRESENT INVENTION 1. Field of Invention The subject invention relates generally to a series of natural pharmaceutical preparations which can treat hypoproteinemia for increasing albumin. The preparations could be used to treat hypoproteinemia caused by hepatitis virus, human

Antibodies to IL-6 to inhibit or treat inflammation

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The sequence listing in the file named "43272ol1805.txt" having a size of 341,671 bytes that was created Apr. 3, 2014 is hereby incorporated by reference in its entirety. BACKGROUND 1. Field of the Art This invention is an extension of Applicants' prior invention disclosed in the above-referenced

Human immunosuppressive protein

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND 1. Technical Field The invention is in the fields of drug therapy; more specifically, the invention encompasses a protein for immunosuppression. 2. The Prior Art The central nervous system (CNS) actively maintains immune privilege (Carson and Sutcliffe, 1999; Fabry et al., 1994), in part

Method for treating allergic dermatitis

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION The present disclosure relates to the treatment of allergic dermatitis, and in particular to allergic dermatitis resulting from contact with naturally-occurring hydrophobic toxins such as urushiol and isosolenopsin A. BACKGROUND OF THE INVENTION Allergic dermatitis can be

Leukotriene by amides and hydrazides

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

RELATIONSHIP TO THE PRIOR ART The concept of using conjugates of leukotrienes in a radioimmunoassay was described, by L. Levine, R. A. Morgan, R. A. Lewis, K. F. Austin, D. A. Clark, A. Marfat, and E. J. Corey, Proceeding of the National Academy of Sciences, U.S.A., Vol. 78, No. 12 7692 (1981) This

Conjugates of leukotrienes with proteins

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Anti-tumor necrosis factor-alpha agents and uses thereof

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION The present invention relates to anti-Tumor Necrosis Factor polypeptides comprising one or more antibody single variable domains, or antigen-binding fragments thereof, in particular, dimers comprising two light chain variable domains that have high solubility. It also relates

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye